Seph Jensen, Chief Executive Officer of TearLab Corporation, graduated from Flagler College in 1994 with a double major in business administration and marketing, and a minor in advertising.
Seph started his career at ADP as the top sales person in the Orlando region. He then moved to Jacksonville to take a position with Warner Lambert. In 1996, Seph joined Alcon Laboratories where he embarked on a 17-year tenure serving in the pharmaceutical and medical device sectors. His roles included various commercial positions with focus in sales and marketing. His time with Alcon was split between local markets within the US and Japan along with Alcon headquarters in Fort Worth, TX. In 2012, Seph was promoted to the Head of Surgical Marketing, and was responsible for over $1.4 Billion in revenue.
In October 2013, Seph joined TearLab as the President and Chief Operating Officer and, as a seasoned leader with in-depth knowledge in the eye care category and a strong track record of delivering operational excellence and profitable growth, is poised to continue the company’s growth and success.
Lior Shav is a General Partner at Accelmed where he focuses primarily on buyout transactions. Lior has over 20 years of experience in business development, investment banking and consulting, primarily in the healthcare space including M&A deals, private placements, private equity transactions, PIPEs and other financial transactions. Prior to joining Accelmed Lior served in different Business Development roles and established and managed Shav Consulting, an Israeli healthcare business consulting firm. Before that Lior managed the corporate finance activity of Meitav Capital Markets and served as an analyst in Meitav Corporate Finance Consultant, both subsidiaries of Meitav, one of Israel largest investment management groups. Lior was a co-founder of ETView Ltd. (TASE listed, MedTech company sold in 2016 to Ambu) as well as two other startup companies. Mr. Shav earned a B.Sc. in Industrial Engineering & Management from the Technion-Israel Institute of Technology in 2001 and a M.A. in Political Science from Tel Aviv University in 2005.
Dr. Lindstrom is the founder and attending surgeon at Minnesota Eye Consultants, Adjunct Clinic Professor Emeritus at the University of Minnesota Department of Ophthalmology, and visiting professor at the UC Irvine Gavin Herbert Eye Institute. He is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive, glaucoma and laser surgery. He has been at the forefront of ophthalmology's evolutionary changes throughout his career, as a recognized researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon.
After graduating Magna Cum Laude from the College of Liberal Arts at the University of Minnesota, Dr. Lindstrom completed his doctorate degree in medicine in 1972. He conducted research, residency and fellowship training in cornea at the University of Minnesota and affiliated hospitals and extended his anterior segment surgery fellowship training at Mary Shiels Hospital in Dallas followed by a Heed Fellowship in Glaucoma at University Hospital in Salt Lake City, after two years of private practice in Dallas, TX. In 1980 Dr. Lindstrom returned to the University of Minnesota, where he spent ten years on the faculty of the Department of Ophthalmology, the last two as a full professor and the Harold G. Scheie Research Chair. He continues as Adjunct Clinical Professor Emeritus, Chairman of the Vision Foundation, a board director for the University of Minnesota Foundation and Associate Director of the Minnesota Lions Eye Bank. He entered private practice in 1989 and has led the growth and expansion of Minnesota Eye Consultants having served as managing partner for 15 years. He is also CO-medical director of Precision Lens and Refractec. He is Chief Medical Editor of the USA and International editions of Ocular Surgery News, which reaches 82,000 ophthalmologists worldwide.
Dr. Lindstrom served as President (2007-2008) of the American Society of Cataract and Refractive Surgery; he also served as chair for 6 years and continues on the Executive and is for the ASCRS and its Foundation. He has also served as the President of the International Society of Refractive Surgery of the American Academy of Ophthalmology, The International Intraocular Implant Club, and the International Refractive Surgery Club.
He has served for 20 years Chairman and CEO of Lindstrom Cleaning and Construction, a three-generation family business. He has endowed funds supporting the University Of Minnesota Department Of Ophthalmology, the Eye Bank Association of America, and the University of Minnesota Tennis Team.
Dr. Lindstrom has been awarded over 40 patents in ophthalmology and has developed a number of corneal preservation solutions, intraocular lenses and instruments that are used in clinical practices globally. He serves on the Board of Directors of Lindstrom Restoration, Minnesota Eye Consultants, TearLab, Ocular Therapeutix, Imprimis, Refractec, AcuFocus, Encore, ForSight#6, IICayr, Alphaeon, Aviana, PogoTec, Equinox, Precision Lens, Iantech, Visionary Ventures, and Flying L Ventures. Prior Boards of acquired companies include: Eyeonics, Advanced Vision Science, Midwest Surgical Services, Laserboyz, Citation Ventures, LVCI Vision, TLC Vision, Sightpath, Onpoint Medical Diagnostics, Vision Twenty-One, Occulogix and Wavetec. Not for profit Board service includes: The University of Minnesota Foundation, University of Minnesota Vision Foundation, InnerCityTennis, Minnesota Eye Consultants Foundation, the ASCRS Executive committee and Foundation Board, The International Society of Refractive Surgery of the American Academy of Ophthalmology.
A frequent lecturer throughout the world on cornea, cataract, glaucoma, laser, and refractive surgery, he has presented over 40 named lectures and keynote speeches before professional societies in the U.S. and abroad, most recently giving the Kelman Lecture at the American Academy of Ophthalmology, the Castroviejo Lecture at the Cornea Society. The Blumenthal Memorial lecture in Jerusalem, Israel, the Benedetto Strampelli Medal Lecture in Rome, Italy, and the Albrecht von Garefe-Vorlesung Innovator’s Lecture in NureNberg, Germany.
Dr. Lindstrom serves on a number of journal editorial boards, including JCRS and JRS. He is the Honorary Editor-in-Chief of the U.S./Chinese Journal of Ophthalmology. He has co-edited seven books, published over 350 peer reviewed journal articles and 60 book chapters. His professional affiliations are extensive.
He is the recipient of numerous awards for distinguished service by national and international ophthalmology associations, including the LANS, Barraquer and the first lifetime achievement award from the International Society of Refractive Surgery in October 1995 and also was honoured with A SECOND lifetime achievement award in October 2002, the Binkhorst and Kelman Lecture Award from the American Society of Cataract and Refractive Surgery, the Bausch and Lomb Lifetime Achievement Award, April 2005, and the Paton Award and NACT Award from the Eye Bank Association of America.
Dr. Lindstrom lives in Minneapolis on the shores of Lake Minnetonka with his wife Jaci and has two children and 5 grandchildren.
Dr. Rafaeli has served as Chief Executive Officer of PhootooMedex Inc (NASDAQ: PHMD) from December 2011 until May 2017. Previously, starting in 2006, he served as president and CEO of Radiancy IInc. (a private company that was merged into PhootoMedex) He has over 30 years of experience managing international operations.
Prior to joining Radiancy, Inc., Dr. Rafaeli served from 2004 to 2006 as president and CEO of the USR Group, a consumer electronics products manufacturer, managing operations in Israel, China, Hong Kong and the U.S. Between 2000 and 2004, Dr. Rafaeli founded and served as general manager of Orbotech Ltd. (ORBK-NASDAQ), an automated optical inspection capital equipment manufacturer for the electronics industry in China and Hong Kong, where he was instrumental in building these operations into a $100 million a year business. Between 1997 and 2000, Dr. Rafaeli served as CEO of USR Ltd., a global electronics contract manufacturing company providing design, supply chain and manufacturing services to dozens of clients in the communications, consumer and medical device fields. USR Ltd. employed approximately 1,000 individuals.
Dr. Rafaeli previously served as director of operations and manager of the Arad manufacturing facility for Motorola in its Land Mobile Product Solutions division, manufacturing and distributing communications, consumer and other infrastructure electronics products in excess of $400 million annually. He received honors as the 2013 Deloitte Technology Fast 500™ ranked #131 with 925% revenue growth, the 2014 Deloitte Technology Fast 500™ ranked #90 with 1301% revenue growth, the 2018 Deloitte Technology Fast 500™ ranked #38 with 3338% revenue growth, Investment Deal of the Year, award winner for the SmartCEO Magazine, finalist for the Ernst & Young 2013 Entrepreneur of the Year.
He has extensive experience in mergers and acquisitions, both domestically and internationally, and particularly involving public company acquisitions, including Photomedex Inc. (formerly, Nasdaq:PHMD), LCA Vision, Inc. (formerly, Nasdaq: LCAV). Currently he serves as the president and CEO and a member of the board of directors of Strata Skin Sciences (Nasdaq:SSKN), and has previously served on the boards of FC Global Realty (NASDAQ:FCRE) and Gadsden Properties Inc. (NASDAQ:GADS).
Dr. Rafaeli graduated with a B.Sc. in industrial engineering and management cum laude and a M.Sc. in operations management from the Technion-Israel Institute of Technology, and holds a Ph.D. in business management from Century University and an MBA (with distinction) from Cornell University.
Ophthalmologist; Co-Founder and CEO of Notal Vision, Co-Founder of Vision6, Pres-by, Azura Ophthalmics, Cameraeyes, and Venture Partner at Accuitive Medical Ventures
Dr. Uri Geiger has served as Managing Partner of Accelmed, a private equity investment firm he co-founded in 2009 focused on medical device companies. Prior to founding Accelmed, Dr. Geiger served as the CEO of Exalenz Bioscience Ltd., a medical technology company, from May 2006 until December 2008. Prior to that, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components from 2001 until 2003. Dr. Geiger was also the founding partner of Dragon Variation Fund in 2000, one of Israel's first hedge funds, which was sold to Migdal in 2007.
Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of and significant experience in capital markets. Dr. Geiger was formerly an adjunct professor at Tel Aviv University's Recanati School of Business where he lectured on private equity and venture capital and authored the books "Startup Companies and Venture Capital" and "From Concept to Wall Street."
He earned his doctorate from New York’s Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger previously served on the board of directors of EndoChoice Holdings Inc. from January 2014 until March 2016.
Uri Geiger brings extensive entrepreneurial, management and investment know-how having created and built many successful medical device enterprises.
Dylan Harmon has served as a Director since July 2020. Mr. Harmon is a member of the Investment Team at CRG, a premier healthcare investment firm that manages over $3 billion of capital. Mr. Harmon’s primary responsibilities at CRG are identifying, assessing, and executing new investment opportunities as well as monitoring existing portfolio companies. Prior to joining CRG, Mr. Harmon served on the Investment Team at Longitude Capital. There he focused on investing in biotechnology companies and was actively involved in portfolio company operations. Previously, Mr. Harmon was a member of the Healthcare Investment Banking Group at Bank of America Merrill Lynch.
Mr. Harmon received a Bachelor's degree in Applied Economics and Management from Cornell University and an MBA in Health Care Management from the Wharton School at the University of Pennsylvania.